Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares Sold by Royce & Associates LP

Royce & Associates LP decreased its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 17.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 287,207 shares of the medical instruments supplier’s stock after selling 59,938 shares during the period. Royce & Associates LP owned 5.29% of Mesa Laboratories worth $37,874,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of MLAB. Amalgamated Bank boosted its holdings in shares of Mesa Laboratories by 6.5% in the 3rd quarter. Amalgamated Bank now owns 1,588 shares of the medical instruments supplier’s stock valued at $206,000 after buying an additional 97 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Mesa Laboratories by 21.8% in the 3rd quarter. Principal Financial Group Inc. now owns 35,107 shares of the medical instruments supplier’s stock valued at $4,559,000 after buying an additional 6,292 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Mesa Laboratories by 90.3% in the 3rd quarter. Victory Capital Management Inc. now owns 14,001 shares of the medical instruments supplier’s stock valued at $1,818,000 after buying an additional 6,643 shares in the last quarter. Cornercap Investment Counsel Inc. acquired a new position in shares of Mesa Laboratories in the 3rd quarter valued at $493,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Mesa Laboratories in the 3rd quarter valued at $449,000. Institutional investors and hedge funds own 90.60% of the company’s stock.

Mesa Laboratories Trading Up 3.1 %

Shares of Mesa Laboratories stock opened at $126.18 on Friday. The company has a fifty day simple moving average of $139.38 and a 200-day simple moving average of $129.36. Mesa Laboratories, Inc. has a 12-month low of $83.68 and a 12-month high of $155.12. The company has a current ratio of 0.71, a quick ratio of 0.53 and a debt-to-equity ratio of 0.61. The stock has a market cap of $685.66 million, a price-to-earnings ratio of -2.73 and a beta of 0.82.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%. On average, equities analysts forecast that Mesa Laboratories, Inc. will post 8 EPS for the current fiscal year.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Investors of record on Friday, February 28th will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.51%. The ex-dividend date of this dividend is Friday, February 28th. Mesa Laboratories’s dividend payout ratio is currently -1.38%.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.